Ocena wrazliwosci na metronidazol i wankomycyne szczepow Clostridium difficile izolowanych z przewodu pokarmowego chorych z biegunka poantybiotykowa [AAD] hospitalizowanych w latach 1998-2002

• Autorzy: Pituch H. , Obuch-Woszczatynski P. , Glinka D. , Lazinska B. , Meisel-Mikolajczyk F. , Luczak M.
• Języki publikacji: PL

Abstrakty

PL

Wykazano wysoką wrażliwość na metronidazol i wankomycynę klinicznych szczepów C. difficile wyhodowanych z próbek kału pobranych od dorosłych z biegunką poantybiotykową hospitalizowanych w latach 1998-2002 w PSK Dzieciątka Jezus - Centrum Leczenia Obrażeń AM oraz dzieci hospitalizowanych w warszawskich szpitalach dziecięcych na oddziałach hematologii i gastroenterologii.

EN

The drugs of choice used to treat C. difficile associated diarrhoea (CDAD) are metronidazole and vancomycin. C. difficile strains isolated in most laboratories are sussceptible to metronidazole and vancomycin. Communication about emergence of antimicrobial resistance among C. difficile strains in some countries to metronidazole and intermidiate resistance to vancomycin are alarming. This study was performed to determine the susceptibility to metronidazole and vancomycin of 140 C. difficile strains isolated from patients with CDAD hospitalised in academic hospital between 1999 - 2002. Resistance to metronidazole and vancomycin was not observed.

Słowa kluczowe

PL

szczepy bakteryjne; metronidazol; biegunki poantybiotykowe; Clostridium difficile; wankomycyna; leczenie; wrazliwosc na metronidazol; zakazenia szpitalne; wrazliwosc na wankomycyne

• Wydawca: -
• Czasopismo: Medycyna Doświadczalna i Mikrobiologia
• Rocznik: 2003
• Tom: 55
• Numer: 3
• Opis fizyczny: s.253-258,rys.,bibliogr.

Twórcy

autor

Pituch H.

• Akademia Medyczna, Warszawa

autor

Obuch-Woszczatynski P.

autor

Glinka D.

autor

Lazinska B.

autor

Meisel-Mikolajczyk F.

autor

Luczak M.

Bibliografia

• 1. Barbut F, Petit JC. Epidemiology of Clostridium difficile-associated infections. C Microbiol Infect 2001; 7: 405-10.
• 2. Bliss D, Johnson S, Savik K i inni. Acquisition of Clostridium diffcile Clostridum difficile-associated diarrhea in hospitalized patients receiving tube feeding. Ann Intern Med 1998; 129: 1012-9.
• 3. Bolton RP, Culshaw MA. Faecal metronidazole concentrations during oral and intravenous therapy from antibiotic associated colitis due to Clostridium difficile. Gut 1987; 27:1169-72.
• 4. Boriello SP. Pathogenesis of Clostridium difficile infection. J Antimicrobiol Chemother 1998; 41: 13-9.
• 5. Brazier JS. The epidemiology and typing of Clostridium difficile. J Antimicrobiol Chemother 1998; 41:47-57.
• 6. Dworczyński A, Sokół В, Meisel-Mikołajczyk F. Antibiotic resistance of Clostridium difficile isolates. Cytobios 1991; 65: 149-53
• 7. Fekety R. Guidelines for the diagnosis and management of Clostridium difficile associated diarrhea and colitis. Am J Gastroenterol 1997; 92: 739-50.
• 8. Gorbach SL. Antibiotics and Clostridium difficile. N Engl J Med 1999; 341: 1690- 92.
• 9. Jang SS, Hansen LM, Breher JE i inni. Antimicrobial susceptibilities of equine isolates of Clostridium difficile and molecular characterization of metronidazole-resistant. Clin Infect Dis 1997; 25: 266-7.
• 10. Kato H, Kato N, Katow S i inni. Deletions in the repeating sequences of the toxin A gene of toxin A-negative, toxin В positive Clostridium difficile strains. FEMS Microbiol Lett 175: 197-203
• 11. Kyne L, Kelly CP. Reccurent Clostridium difficile diarrhea. Gut 2001; 49:152-53.
• 12. Mc Coubrey J, Martin H, Starr JM i inni. Clostridium difficile in a geriatric unit: a prospective study. An international Congress of the Confederation of Anaerobe Societies. Abstract Book „Anaerobe". 2000.10-12 VII. 2000 abst. nrVIII-02 str. 166.
• 13. Mylonakis E, Ryan ET, Calderwood SB. Clostridium difficile-associatd diarrhoea: a review. Arch Intern Med 2001; 161: 525-33.
• 14. National Committee for Clinical Laboratory Standards. 2001. Methods for antimicrobial susceptibility testing of anaerobic bacteria; approved standard, 5th ed. NCCLS document M11-A5. National Committee for Clinical Laboratory Standards, Wayne, Pa.
• 15. Pelaez T, Sanchez R, Blazauez R.i inni. Metronidazole resistance in Clostridium difficile: a new emerging problem? Program and abstracts of the 34th Internsci Conf Antimicrob Agents and Chemother 1994, E-34: 50
• 16. Pelaez T, Alcala L, Alonso R i inni. Reassesment of Clostridium difficile susceptibility to metronidazol and vancomycin. Antimicrob Agents Chemoth 2002; 46: 1647-50.
• 17. Pituch H, van den Braak N, van Leeuwen W i inni. Clonal dissemination of a toxin A -negative/toxin B- positive Clostridium difficile strains from patients with antibiotic-associated diarrhea in Poland. Clin Microbiol Infect 2001; 7: 442-6.
• 18. Pituch H. Flora bakteryjna izolowana z kału osób z podejrzeniem biegunki poantybiotykowej. Rozprawa doktorska. 2002. Akademia Medyczna w Warszawie.
• 19. Poxton IR, McCoubray J, Blair G. The pathogenicity of Clostridium difficile. Clin Microbiol Infect 2001; 7: 421-7.
• 20. Tabaąchali S, Jumaa P. Diagnosis and management of Clostriidum difficile infection. B. M. J. 1995; 310: 1375-80.
• 21. Wong S S, Woo PC, Luk WK i inni. Susceptibility testing of Clostridium difficile against metronidazol and vancomycin by disc diffusion and E-test. Diagn Microbiol Infect. Dis 1999; 34: 1-6.